Here are three points:
1. Seres Therapeutics is collaborating with researchers at the Research Institute of St. Joseph’s Hamilton in Canada and the Medical University of Graz in Austria.
2. Under the agreements, the academic institutions enhance the company’s efforts to develop microbiome-based therapeutics for IBD.
3. Seres’ pipeline includes SER-287 and SER-301. SER-287 is the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease.
More articles on GI/endoscopy:
Texas Medical Association names Dr. Carlos Cardenas president-elect: 3 points
Mederi Therapeutics launches 3rd generation of Stretta technology: 5 things to know
Boston Scientific’s net sales of $1.96B in Q1 2016: 7 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
